Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial

ConclusionsThe efficacy of adding bavituximab to sorafenib for the treatment of advanced HCC was inconclusive; however, the combination regimen did not exacerbate toxicities associated with single-agent sorafenib.ClinicalTrials.gov identifierNCT01264705.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research